e-learning
resources
Copenhagen 2005
Tuesday 20.09.2005
Resistant and MDR tuberculosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Attempt to estimate risk factors for drug resistance (DR) in tuberculosis
A. Macri, O. Moldovan, A. Hristea, C. Stefani (Bucharest, Romania)
Source:
Annual Congress 2005 - Resistant and MDR tuberculosis
Session:
Resistant and MDR tuberculosis
Session type:
Thematic Poster Session
Number:
4134
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Macri, O. Moldovan, A. Hristea, C. Stefani (Bucharest, Romania). Attempt to estimate risk factors for drug resistance (DR) in tuberculosis. Eur Respir J 2005; 26: Suppl. 49, 4134
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
The risk of ineffective MDR/XDR TB treatment, based on bedaquilin: factors and their influence
Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis
Year: 2020
Frequency of side effects among patients with drug resistant tuberculosis (DR-TB) by resistance pattern in a high burden country.
Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis
Year: 2020
Outcome of multidrug resistant tuberculosis (MDR-TB) treatment with possible influencing factors
Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis
Year: 2011
Recent transmission of drug resistant
M. tuberculosis
in Latvia
Source: Annual Congress 2005 - Resistant and multidrug resistant tuberculosis
Year: 2005
The problem of multi-drug resistant (MDR)-TB
Source: Annual Congress 2005 - PG10 - The management of tuberculosis: tradition and novelties
Year: 2005
HIV and multidrug-resistant tuberculosis: overlapping risk factors
Source: Eur Respir J 2015; 45: 567-569
Year: 2015
The impact and cost-effectiveness of strategies to detect drug-resistant tuberculosis
Source: Eur Respir J 2012; 39: 626-634
Year: 2012
Contact screening in tuberculosis. Can we identify those with higher risk?
Source: Annual Congress 2012 - Tuberculosis: epidemiological and public health features
Year: 2012
Identification of high risk factors for development of active tuberculosis in children with latent tuberculosis infections
Source: International Congress 2017 – Clinical challenges in chronic lung diseases
Year: 2017
Is it smoking a risk factor in tuberculosis?
Source: Annual Congress 2010 - Tuberculosis: metabolic insights
Year: 2010
Smoking is a risk factor for TB infection, but is it an additional mortality risk?
Source: Annual Congress 2011 - Management of tuberculosis
Year: 2011
Contact screening in tuberculosis: can we identify those with higher risk?
Source: Eur Respir J 2013; 41: 758-760
Year: 2013
Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis
Source: Eur Respir J 2016; 48: 1751-1763
Year: 2016
The prevalence of latent pulmonary tuberculosis infection (LTBI) in low and high risk populations in Ireland
Source: Eur Respir J 2005; 26: Suppl. 49, 425s
Year: 2005
Pyrosequencing(PSQ) in early diagnosis of CNS tuberculosis and determining drug resistance.
Source: International Congress 2019 – Tuberculosis: from basic science to patient care
Year: 2019
Risk factors of development of amplified
Mtb
resistance to antituberculous drugs
Source: Eur Respir J 2005; 26: Suppl. 49, 652s
Year: 2005
Predicting outcomes and drug resistance with standardised treatment of active tuberculosis
Source: Eur Respir J 2010; 36: 870-877
Year: 2010
Who is at risk for active tuberculosis?
Source: Annual Congress 2003 - Latent tuberculosis infection - preventive approaches
Year: 2003
The problem of one drug resistance in tuberculosis
Source: Eur Respir J 2006; 28: Suppl. 50, 858s
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept